C
rohn's disease (CD) and ulcerative colitis (UC) are complex multifactorial disorders that result from aberrant immune responses to gut luminal antigens in genetically susceptible hosts. 1, 2 From the clinical point of view, inflammatory bowel disease (IBD) represents a heterogeneous group of conditions regarding disease location, disease behavior, and clinical course.
In an attempt to explain this diversity, clinical parameters such as young age at diagnosis, early need for steroid treatment and perianal involvement in CD, or various blood-derived biomarkers proved to be disappointing in predicting disease behavior. [3] [4] [5] Similarly, several international collaborative genetic studies have so far identified 163 IBD-associated susceptibility loci. 6 This knowledge underlined the immunologic phenomena related to IBD but did not elucidate its pathogenesis and cannot be used as a predictor in treating individual patients. 3, 6, 7 Next to the genetic background of the patient, alterations in T-cell subsets within the gut mucosa seem to play an important role in the pathogenesis of IBD. 8 Bone marrow-derived lymphoid progenitor T cells undergo positive and negative selection in the thymus, resulting in the release of immunocompetent naive T cells in circulation. 9 These naive T cells have previously been thought to circulate exclusively between secondary lymphoid organs, such as peripheral and mesenteric lymph nodes. 9 However, several reports suggest that naive T cells also enter nonlymphoid organs, such as the intestinal mucosa, especially at the sites of inflammation. [10] [11] [12] Besides an increased amount of naive CD45RA + T cells, which has been described in both CD and UC, 13 differentiated T-cell subpopulations seem to differ between these 2 clinical entities. In CD, the major cytokines interferon g (IFN-g) and interleukin 17 are derived from T helper 1 (Th1) and Th17 cell differentiation, respectively, 14 whereas UC has been shown to be predominantly driven by a Th2-like differentiation process, leading to the expansion of natural killer T cells and production of the cytokines IL-4 and IL-13.
1,2 Furthermore, other cytokine profiles have been associated with both forms of IBD such as the proinflammatory cytokines, tumor necrosis factor a [TNF-a] and IL-6, and the regulatory cytokines, IL-10.
8,14
Notably, these immunologic typologies were mainly based on experimental studies in murine models, 15, 16 whereas, studies on T cells in the intestinal mucosa of humans have typically been performed in patients with IBD who were under treatment with immune-modulating therapies. [17] [18] [19] Here, we have determined the distribution of different T-cell subpopulations and their related cytokine profiles in the gastrointestinal mucosa of newly diagnosed, untreated adult patients with IBD. We show that variations in T-cell subpopulations in the gut mucosa, early in the course of disease, were associated with different clinical subtypes of IBD and may, in future, help to stratify patients who are likely to respond to a certain therapy.
MATERIALS AND METHODS

Patients and Controls
Patients with symptoms of chronic diarrhea, rectal blood loss, abdominal pain, or weight loss underwent combined ileocolonoscopy and upper endoscopy. From this group, 51 newly diagnosed patients with CD and 14 newly diagnosed patients with UC were included in the study. The diagnosis of IBD was established and certified by clinical, endoscopic, and histological standard criteria. 20 Endoscopic severity of disease activity was assessed using the simple endoscopy score for CD (SES-CD) and the full Mayo score for UC. 21 Following the standardized diagnostic procedures, comprising laboratory tests, endoscopy, and, if needed, additional imaging techniques, all patients with IBD were classified according to the clinical phenotype at diagnosis using the Montreal classification, although this is confidently established after a 5-year follow-up. 22 Controls were recruited from a patient population who underwent endoscopy for other reasons. Control biopsies were taken from 14 individuals who underwent ileocolonoscopy for polyp/cancer screening and from 10 individuals who underwent upper endoscopy because of functional dyspepsia, showing no signs of gastrointestinal pathology during endoscopic and histological examination.
Baseline clinical characteristics according to the Montreal classification at initial presentation and demographic data of all included patients and controls are presented in Table 1 .
Tissue Samples and Cell Preparation
Mucosal biopsy specimens were sampled before any antiinflammatory (IBD) treatment. During colonoscopy, biopsies were harvested from the macroscopically most inflamed region of the colon and ileum. In addition to biopsies taken for histopathologic examination, 4 biopsies from the terminal ileum and 4 from the colon were taken for immunologic determination. During upper endoscopy, 4 mucosal biopsies of normal gastric corpus and antrum and 2 biopsies of normal duodenal mucosa were taken for histopathologic examination and 2 additional biopsies for immunologic examination. When endoscopic lesions were observed, biopsies for immunologic examination were specifically harvested from macroscopic lesions, such as erosions or ulcerations. All biopsy specimens from apparently healthy individuals were sampled from macroscopically normal mucosa.
Biopsy samples were kept in phosphate-buffered saline solution at 2 to 88C and were processed within 8 hours. All samples were finely minced in Hanks'/1% bovine serum albumin using a 70-mm gaze and spatula followed by Ficoll density gradient centrifugation. After washing, the homogenate was resuspended in 0.5 mL Hanks'/1% bovine serum albumin and the cell number was estimated by microscopic counting using a KOVA glasstic slide (Hycor Biomedical Ltd., Penicuik, United Kingdom). From the total cell suspension, 200 mL was used for flow cytometric analysis disregarding absolute cell number. When the total cell number was .1 · 10 6 /mL, the remaining cell suspension was incubated overnight at 378C in the presence of 1 mg/mL phorbol myristate acetate (PMA)/1 mM ionomycin to assess cytokine secretion.
Flow Cytometry and Cytokine Assays
Flow cytometric immunophenotyping encompassed three 6-color analyses: mix 1: CD19-FITC, CD7-PE, CD45-PerCP/CY5.5, Naive and memory T-cell profiles were studied in colon/ ileum biopsies by analyzing the combination of CD45RA and CD27 expression. 23 The CD45RA + CD27 + population was defined as the naive T-cell subset, the CD45RA 2 CD27 + as the central memory T-cell subset, and the CD45RA 2 CD27 2 as the effector memory T-cell subset. 23 Additionally to the phenotypic identification, mucosal T cells were functionally characterized by stimulating the cell suspensions from biopsies with PMA/ionomycin. After overnight stimulation, the supernatants were frozen for flow cytometric cytokine analysis using BD Cytometric Bead Array (BD Biosciences). Levels of IL-2, IL-4, IL-6, IL-10, TNF-a, IFN-g, and IL-17 were reflected to standard concentrations of the respective proteins and initially expressed in picograms per milliliter. However, as cytokine levels measured in the supernatant of overnight incubated cell suspensions were dependent on the cell number in the culture and the relative T-cell number, the individual cytokine levels were expressed as a percentage of the total excreted cytokine level instead of picograms per milliliter.
Statistical Analysis
Data are shown as mean 6 SD, as median in case of nonGaussian distribution, or as values for individual specimens in the figures. The Mann-Whitney nonparametric U test was used for determination of statistical significance. Values of P # 0.05 were considered to be significant.
ETHICAL CONSIDERATIONS
Regional medical ethics committee approval was obtained before commencement of the study, and all patients provided written informed consent. The study was performed according to the principles of the Declaration of Helsinki.
RESULTS
Distribution of Lymphocytes in Mucosa of Duodenum and Ileum/Colon
To assess the distribution of lymphocyte subsets in duodenum and ileum/colon, we determined their numbers in patients with IBD and healthy controls.
In the lymphocyte population of the duodenum in patients with IBD, T cells were predominant (74% in CD and 75% in UC), with low frequencies of B cells (4% in CD and 9% in UC). The median CD4/CD8 ratio in duodenum was 1:3 in patients with CD and 1:2 in those with UC. Most of the duodenal T cells were of mucosal origin (CD103 + ): 81% in CD and 84% in UC ( Fig. 1 and Table 2 ). Furthermore, B cells were more in number in the ileum and colon of patients with IBD than in the duodenum, with a median of 34% and 38% of the lymphocyte population in CD and UC, respectively. In both CD and UC, T cells represented 56% of the lymphocytes, of which a minority was of mucosal origin (CD103 + ): 15% in CD and 11% in UC. The mean CD4/CD8 ratio in ileum/colon was 2,3:3 in CD and 3,2:2 in UC. The frequencies of CD25 high FoxP3 + Tregs in ileum/colon were 14% in CD and 13% in UC ( Fig. 1 and Table 2 ).
In healthy control samples, the distribution of B-and T-cell numbers in duodenum and ileum/colon was comparable with that of patients with IBD. However, the number of Tregs (CD25 high FoxP3 + ), nonmucosal (CD103 2 ) T cells, and the CD4/CD8 ratio in the ileum/ colon were significantly higher in patients with IBD compared with controls ( Fig. 1 and Table 2 ).
Naive and Memory T-cell Profiles in Ileum/ Colon Mucosa of Patients with IBD and Controls
Within the CD3 + T-cell population present in ileum/colon, naive and memory T-cell profiles were studied by analyzing expression of CD45RA and CD27. 23 The CD45RA + CD27 + population was defined as the naive (T N ), the CD45RA 2 CD27 + as the central memory (T CM ), and the CD45RA 2 CD27 2 as the effector memory (T EM ) T-cell subset.
Patients with IBD showed a higher frequency of T N cells compared with controls (31% in CD and 28% in UC versus 19% in controls). Additionally, patients with IBD also showed an increased number of T CM cells (37% in CD and 42% in UC versus 25% in controls). In contrast, the number of the T EM cells was lower in patients with IBD compared with controls (20% in CD and 19% in UC versus 33% in controls).
Within the ileum/colon mucosa of patients with IBD, we observed a remarkable variability in the frequencies of naive and memory T cells. We identified 4 different profiles (profile A-D), which consisted mainly (.40%) of CD45RA + CD27 + naive T cells (profile A), CD45RA 2 CD27 + central memory T cells (profile B), CD45RA 2 CD27 2 effector memory T cells (profile C), or an equal (each approximately 30%) distribution of these aforementioned subpopulations (profile D, Fig. 2A) . The T N and T CM cells were mostly nonmucosal (CD103 2 ) CD4 + T cells, whereas the T EM cells were mostly CD8 + T cells of mucosal origin (CD103 + ) (Fig. 3) .
Notably, the mainly naive T-cell profile A was only observed in patients with IBD, whereas the mixed T-cell profile D was only present in controls. In patients with IBD, the T-cell profile B, with mostly central memory T cells, was the most predominant. However, we did not observe significant different profiles between patients with CD and UC (Fig. 2B ).
Cytokine Levels in Different Maturation T-cell Profiles of Patients and Controls
In addition to the phenotypic identification, cytokine production by mucosal T cells from ileum/colon was characterized by stimulating biopsy-derived cell suspensions for 24 hours with PMA/ionomycin (Fig. 4) . The number of lymphocytes in duodenum was too low to perform stimulation assays.
Supernatants from ileum/colon biopsies containing high numbers of naive T cells (profiles A and B) produced more TNF-a compared with the supernatants of biopsies containing predominantly T EM cells (profile C). TNF-a levels as percentage of total measured cytokines from biopsies with T-cell profiles A and B were 30% and 26%, respectively, versus 17% from biopsies with T-cell profile C (P ¼ 0.004) in CD; 32% in A and 20% in B versus 19% in C (P ¼ 0.12) in UC (Fig. 4A) . In addition, these cells produced lower amounts of IFN-g (47% in A and B versus 66% in C [P ¼ 0.003] in CD; 47% in A and 37% in B versus 63% in C [P ¼ 0.34] in UC) (Fig. 4B) . In contrast, patients with IBD with mainly T EM cells (profile C) produced more IL-17 and less IL-10 compared with the more naive A and B profiles (Fig. 4C, D) .
T-cell Maturation Profile in Patients with CD is Associated with the Clinical Phenotype at Presentation
To determine the clinical value of immunophenotypic T-cell profiling in mucosa of patients with IBD, we correlated the observed profiles with the clinical phenotype. We found that in patients with CD, profile A was associated with upper gastrointestinal tract involvement (65%) and perianal disease at presentation (75%). However, there was no association between the immunologic profiles and the disease extension in patients with UC or with the endoscopic disease activity scored by SES-CD and endoscopic Mayo score.
In summary, we describe 3 immunologic subgroups in early-stage, untreated adult patients with IBD characterized by different number of naive and memory T-cell subsets in the gut mucosa. Remarkably, cytokine levels differ significantly between these profiles and we observed an association with clinical phenotype at presentation.
DISCUSSION
In this study, we have analyzed T-cell subsets in the gut mucosa of a large cohort of newly diagnosed, untreated adult patients with IBD. CD19 + B cells were particularly located in ileum/colon, whereas CD3 + T cells were the major lymphocytic Numbers (with exception of CD4/CD8 ratio) are percentages of lymphocyte population, characterized by light scatter characteristics and CD45 expression. Representative fluorescenceactivated cell sorting plots for each staining are shown in Figure 1 . C, controls; NS, nonsignificant. the subgroup with predominant T EM cells (profile C, CD45RA 2 CD27 2 ).
Cells derived from patients with IBD with mainly T EM cell phenotype (profile C) secreted increased levels of IFN-g and IL-17 compared with the other profiles, reflecting a predominant Th1/Th17 response in this subgroup of patients with IBD. Furthermore, higher frequencies of naive T cells in patients with CD correlated with more extended and penetrating disease, reflecting a more aggressive presentation.
In healthy controls, lower frequencies of T N cells (CD45RA + CD27 + ) and relative higher number of T cells from mucosal origin (CD103 + ) were found. These findings, as well as higher frequencies of B cells in colon versus duodenum, are in line with a recent study of human T-and B-cell compartmentalization in healthy subjects. 10 Although the paradigm is that only activated and memory T cells have access to nonlymphoid tissues, such as the gut mucosa, it has been shown that naive T cells are also able to access parenchymal tissues. 24 Previously, it has been demonstrated that transfer of naive T cells (CD4 + CD45RB + ) in T cell-deficient mice can cause an IBD-like syndrome. 15, 16 In humans, there have been a limited number of studies investigating the recruitment of naive T cells to the gut mucosa of patients with IBD, who were all under immunosuppressive treatment. A relatively high number of naive T cells (CD4 + CD45RB high CD45RA + ), producing a high amount of TNF-a and a low amount of IFN-g, have been described in the intestinal mucosa of both CD and UC. 13 This has been confirmed by demonstrating the presence of CD45RA + T cells in the inflamed mucosa of 5 patients with UC. 25 Increased levels of truly naive T cells, which have not encountered cognate antigen for their specific T-cell receptor (also known as recent thymic emigrants), have also been described in the mucosa of treated patients with UC, irrespective of disease activity. 26 In contrast, these recent thymic emigrants were not found in patients with CD.
Furthermore, it was recently reported that in patients with IBD, frequencies of mucosal CD4 + CD45RA + T cells were decreased during treatment with corticosteroids or biologicals, whereas frequencies of early activated (CD4 + CD69 + ) and memory T cells (CD4 + CD45RO + ) remained unchanged. 17 This effect of immunosuppressive therapy may explain the discrepancy with the findings of an increased frequency of CD45RA + cells in our cohort of newly diagnosed untreated patients with IBD.
Irrespective of disease phenotype and T-cell maturation profiles, we have detected a higher number of regulatory T cells (Tregs, CD25 high FoxP3 + ) in colon/ileum of patients with IBD compared with controls. In other studies, similar frequencies have been observed in patients with IBD during immunosuppressive therapy, 27, 28 suggesting that the frequency of Tregs is not influenced by such treatment. In mouse models, it has been shown that Tregs are capable to regulate Th1-and Th17-derived colitis by producing high levels of IL-10, which is not yet confirmed in humans. [29] [30] [31] Additionally to IL-10-secreting Tregs, a distinct population of Tregs (FoxP3 + ) producing IL-17 and IFN-g was described in inflamed colon mucosa of patients with CD. 32 Recent data suggest that Th17 and FoxP3 + T cells could be related to or arise from the same precursor, dependent on a distinct cytokine environment. [33] [34] [35] [36] [37] Therefore, the exact role of Tregs in the pathogenesis of IBD remains to be resolved.
In our cohort, cells derived from ileum/colon biopsies with a more naive T-cell profile produced higher levels of TNF-a compared with biopsies with a more effector memory T-cell profile. This finding corroborates the role of TNF-a in the initiation of the immune response, T-cell proliferation, and differentiation as described by others. 38, 39 Different numbers of naive and memory T cells in the gut mucosa of patients with IBD could reflect different stages of the inflammatory process or on different T-cell migration and maturation pathways characterizing different IBD phenotypes.
The effect of neutralizing TNF-a during priming of naive CD4 + T cells was recently studied in vitro. It was shown that anti-TNF-a treatment inhibited T-cell activation and polarized naive T cells toward higher IL-10 and lower IFN-g production. 40 These findings raise the question if early anti-TNF-a therapy in patients with a predominant naive T-cell maturation profile could beneficially influence the course of the disease.
Our data suggest that there are differences in influx of naive T cells in the gut mucosa associated with different levels of proinflammatory cytokines during the early phase of untreated IBD. Further studies will elucidate if the described T-cell maturation profiles reflect different disease phenotypes and provide a rationale for the heterogenic clinical presentation of IBD. The long-term follow-up of this patient cohort may reveal the alleged clinical value of these mucosal T-cell profiles, both with respect to disease progression and response to immunosuppressive therapy.
